Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Zenosense, Inc. engages in developing medical devices for the diagnosis of heart attack and cardiac-related illnesses. It includes the detection of the Methicillin-resistant Staphylococcus aureus. The firm uses Acute Myocardial Infarction, and MIDS Cardiac technologies. The company was founded on August 11, 2008 and is headquartered in New Haven, CT.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.